Please login to the form below
Acquisition
This page shows the latest Acquisition news and features for those working in and with pharma, biotech and healthcare.
Sanofi raises profit forecast following positive Q2 results
Completion of the acquisition of Tidal Therapeutics, Kiadis and Kymab.
Latest news
-
Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
Executing value-enhancing business development is a top priority, and we intend to add to our pipeline through acquisitions, partnerships, licensing deals and collaborations.
-
AZ raises full-year guidance after completing Alexion acquisition in Q2
AstraZeneca has announced that it will raise its full-year 2021 guidance to reflect a boost to its portfolio following the successful acquisition of rare disease company Alexion in the second ... Looking ahead to its full-year results, however, AZ is
-
Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance
Resilience is set to continue investment in the advancement of new technologies and will also expand the workforce upon completion of the acquisition.
-
Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
Following the acquisition, Amgen will also gain Teneobio’s portfolio of antibody assets for oncology targets, which includes the phase 1 trial candidate TNB-585. ... Prior to closing of the Amgen/Teneobio acquisition, three Teneobio affiliate companies
-
AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
In July, AZ completed its acquisition of Alexion, establishing the company as its specialist rare disease unit.
Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
AZ raises full-year guidance after completing Alexion acquisition in Q2
Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance
Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
More from news
Approximately 198 fully matching, plus 1,280 partially matching documents found.
Latest Intelligence
-
Integrating competitive intelligence into business development, licensing and M&A strategy
In many circumstances, there is a need to make assessments of potential acquisition targets without the acquiree being aware of the initial interest. ... In the acquisition assessment process, the development of a TPP is a collaborative effort between
-
Back to the future
Equally, large firms have been slow to adapt both to new technologies and changing customer needs and have resorted to acquisition over organic evolution.
-
Transforming clinical trial data into a long-term asset
On the corporate side, it can come into play in licensing and partnership opportunities, in handling legal challenges and due diligence, and in mergers and acquisitions.
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
the pipeline, the use of technology in medicine is expected to grow and so are the associated deals, mergers and acquisitions. ... They also can help identify collaboration opportunities including partnerships, licensing deals and merger or acquisition
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Another example is Biogen’s $800m acquisition of Nightstar’s late-stage gene therapy assets for retinal disease – NSR-REP1 and NSR-RPGR.
Integrating competitive intelligence into business development, licensing and M&A strategy
Back to the future
Transforming clinical trial data into a long-term asset
Sourcing R&D innovation: why pharma companies need to evolve their business models
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
More from intelligence
Approximately 75 fully matching, plus 95 partially matching documents found.
Latest appointments
-
Fishawack Health restructures creative team
In February, Fishawack announced its acquisition of The Hive Health Group, a healthcare marketing and scientific communications agency with a presence in both the UK and US.
-
Ashfield Advisory adds Mary-Kate McGarry and Emer Jameson to senior leadership team
At Ashfield Advisory, she will be responsible for driving all aspects of the company’s strategy and will work closely with the mergers and acquisitions team, while also oversee the ... We have a strong growth trajectory and plan to accelerate this by
-
Anna Korving joins Resonant Group as non-executive director
Industry veteran Korving previously took a group of agencies from start up through to acquisition by Publicis Health, to create the integrate service offerings Publicis Life Brands Resolute – now known as
-
AZ appoints Alexion’s Aradhana Sarin as chief financial officer
Sarin will become AZ's new chief financial officer upon closing of the company’s acquisition of Alexion Pharmaceuticals. ... At AZ, she will succeed current chief financial officer Marc Dunoyer, who will step down from the role and retire from the
-
Deborah Keller appointed as chair of Fishawack Health’s board
Keller’s appointment follows a number of recent acquisitions at Fishawack, including the healthcare marketing and scientific communications agency The Hive Health Group and the global market access consultancy PRMA Consulting.
Fishawack Health restructures creative team
Ashfield Advisory adds Mary-Kate McGarry and Emer Jameson to senior leadership team
Anna Korving joins Resonant Group as non-executive director
AZ appoints Alexion’s Aradhana Sarin as chief financial officer
Deborah Keller appointed as chair of Fishawack Health’s board
More from appointments
Approximately 0 fully matching, plus 124 partially matching documents found.
Latest from PMHub
-
RESONANT GROUP APPOINTS STEPHEN MARCHANT CHIEF DEVELOPMENT OFFICER
Known in the industry for taking a group of agencies from start up through to acquisition by Publicis Health, Anna built one of the first truly integrated service offerings, Publicis Life
-
RESONANT GROUP APPOINTS STEPHEN MARCHANT CHIEF DEVELOPMENT OFFICER
Known in the industry for taking a group of agencies from start up through to acquisition by Publicis Health, Anna built one of the first truly integrated service offerings, Publicis Life
-
Lucid Group acquires US-based strategic brand consultants DiD
This acquisition will augment the group to become a 400+ people-strong company. ... This is Lucid Group’s first acquisition backed by its new investment partner Intermediate Capital Group (ICG) – a leading global alternative asset manager.
-
Welcoming analytics-driven digital marketing agency closerlook to the Fishawack Health pack
Fishawack Health enhances its omnichannel capabilities with the acquisition of closerlook, a data analytics and digital native healthcare agency specializing in intelligent omnichannel marketing solutions.
-
Our #LucidLife
with one of our talent acquisition managers Daniel Newbury or Lucinda Fowkes.
RESONANT GROUP APPOINTS STEPHEN MARCHANT CHIEF DEVELOPMENT OFFICER
RESONANT GROUP APPOINTS STEPHEN MARCHANT CHIEF DEVELOPMENT OFFICER
More from PMHub
Approximately 12 fully matching, plus 97 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Midweight-Senior Creative
-
Competitive Salary Offered
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Events Executive
-
Depending on Experience
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- CONGREGO™ IS NOW MULTI-PLATFORM
- Onyx Health Marks Record Growth with Six New Appointments
- FDA expands use of COVID-19 antibody cocktail
- New European supply deals show Pfizer and Moderna have increased COVID-19 vaccine prices
- Ipsen’s spending spree bolsters neurology pipeline
- AMICULUM® launches Cence, a new specialist publications agency
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- Eylea set to challenge Lucentis in UK after NICE recommendation
- Onyx Health Launch Creative Studio After Record Year
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
PMHub
Origins Insights
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...
Latest intelligence
- Guide
- How to embrace behavioural science principles in healthcare MR...
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
